Bone Changes With Long-Acting Cabotegravir or Tenofovir Disoproxil Fumarate/Emtricitabine for HIV Prevention in Cisgender Men and Transgender Women: HPTN 083
InfectologiaSobre o estudo
- Desenho
- Ensaio clínico randomizado
- Nível de evidência
- 2 · Nova evidência
- Revista
- Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
- Publicado em
- 24 dez 2025
- Citações
- 2
O resumo deste estudo é do publisher e não tem licença aberta: por isso mostramos aqui só os dados do estudo, e o texto fica na fonte original, nos links abaixo.
O estudo original
Bone Changes With Long-Acting Cabotegravir or Tenofovir Disoproxil Fumarate/Emtricitabine for HIV Prevention in Cisgender Men and Transgender Women: HPTN 083
Todd T Brown, Robert F Arao, Maryam Warsi, Nittaya Phanuphak, Ricardo Vasconcelos, Temitope Oyedele, Philip A Sullivan, Brett Hanscom, James F Rooney, Alex R Rinehart et al.
Descritores MeSH
- Pre-Exposure Prophylaxis
- Tenofovir
- Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination
- Pyridones
- HIV Infections
- Anti-HIV Agents
- Emtricitabine
- Middle Aged
- Diketopiperazines
- Bone Density
Veja também
Estudos relacionados
- Lenacapavir as pre-exposure prophylaxis for HIV prevention
- Efficacy and safety of long-acting cabotegravir versus oral tenofovir disoproxil fumarate-emtricitabine as HIV pre-exposure prophylaxis: A systematic review and meta-analysis
- Exploring potential drug-drug interactions between masculinizing hormone therapy and oral pre-exposure prophylaxis (F/TDF and F/TAF) among transgender men (iMACT study): a randomized, open-label pharmacokinetic study in Thailand
- Evaluation of long-acting cabotegravir safety and pharmacokinetics in pregnant women in eastern and southern Africa: a secondary analysis of HPTN 084